Encouraging news for the estimated 350,000 Americans with Multiple Sclerosis. The Food and Drug Administration has approved the first drug that specifically targets MS.
The drug, called Tysabri, blocks destructive immune cells that, in MS patients, attack the body's central nervous system. Tysabri is still not a cure, but in clinical trials, the drug dramatically reduced the patient flare-ups, which can destroy vision or leave arms and legs paralyzed.
The drug was created by two companies: Massachusetts-based Biogen Idec Incorporated and Irish drug maker Elan Corporation.